GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CARISMA Therapeutics Inc (NAS:CARM) » Definitions » PB Ratio

CARISMA Therapeutics (CARISMA Therapeutics) PB Ratio : 5.23 (As of May. 16, 2024)


View and export this data going back to 2023. Start your Free Trial

What is CARISMA Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-16), CARISMA Therapeutics's share price is $1.37. CARISMA Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 was $0.26. Hence, CARISMA Therapeutics's PB Ratio of today is 5.23.

The historical rank and industry rank for CARISMA Therapeutics's PB Ratio or its related term are showing as below:

CARM' s PB Ratio Range Over the Past 10 Years
Min: 1.32   Med: 3.29   Max: 7.37
Current: 5.27

During the past 4 years, CARISMA Therapeutics's highest PB Ratio was 7.37. The lowest was 1.32. And the median was 3.29.

CARM's PB Ratio is ranked worse than
78.97% of 1322 companies
in the Biotechnology industry
Industry Median: 2.54 vs CARM: 5.27

During the past 12 months, CARISMA Therapeutics's average Book Value Per Share Growth Rate was -87.70% per year.

Back to Basics: PB Ratio


CARISMA Therapeutics PB Ratio Historical Data

The historical data trend for CARISMA Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CARISMA Therapeutics PB Ratio Chart

CARISMA Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
PB Ratio
- - - 4.49

CARISMA Therapeutics Quarterly Data
Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.45 5.30 3.68 4.49 8.66

Competitive Comparison of CARISMA Therapeutics's PB Ratio

For the Biotechnology subindustry, CARISMA Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CARISMA Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CARISMA Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where CARISMA Therapeutics's PB Ratio falls into.



CARISMA Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

CARISMA Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2024)
=1.37/0.262
=5.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


CARISMA Therapeutics  (NAS:CARM) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


CARISMA Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of CARISMA Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


CARISMA Therapeutics (CARISMA Therapeutics) Business Description

Traded in Other Exchanges
Address
245 First Street, Suite 1800, Cambridge, MA, USA, 02142
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
Executives
Modernatx, Inc. 10 percent owner 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Sanford S Zweifach director 21720 23RD DRIVE SE, SUITE 150, BOTHELL WA 98021
Steven Kelly director, officer: President and CEO C/O INNOVIVE PHARMACEUTICALS, INC., 555 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
Briggs Morrison director C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
Richard Steven Morris officer: Chief Financial Officer 397 EAGLEVIEW BOULEVARD, EXTON PA 19341
Chidozie Ugwumba director 158 FILMORE STREET, DENVER CO 80206
Michael Klichinsky officer: Chief Scientific Officer C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Michael Torok director C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Regina Hodits director C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Bjorn Odlander director C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51
Minori Rosales officer: Chief Development Officer 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Jewett Michael A. S. director C/O SESEN BIO, INC., 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Peter Honig director 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Patricia M. Drake officer: Chief Commercial Officer 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Elly Ryu officer: Principal Accounting Officer 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142